SARS-Cov-2 and the Case for Empirical Treatment

Authors

  • Alexandria Watkins

  • Richard P. Bartlett

Keywords:

steroids and coronavirus, the United States with unique cases

Abstract

As of June 17, 2020, Google Trends reports that the topics "steroids and coronavirus" have increased +4,750%.12 This is an outpatient case study that examines two patients in the United States with unique cases that involve oncology and Severe Acute Respiratory Syndrome Coronavirus-2 (SARSCoV- 2), also known as COVID-19. This case study aims to reveal the identification process, diagnosis, clinical course, and management of such a distinctive case - including the patient's prodromal phase and subsequent progression of the disease in an outpatient setting utilizing telemedicine. The goal is to call attention to the success of proactive, early empirical treatment, combining a classic corticosteroid (budesonide) administered via a nebulizer and an oral macrolide antibiotic known as clarithromycin (Biaxin).

How to Cite

Alexandria Watkins, & Richard P. Bartlett. (2020). SARS-Cov-2 and the Case for Empirical Treatment. Global Journal of Science Frontier Research, 20(I4), 1–8. Retrieved from https://journalofscience.org/index.php/GJSFR/article/view/2773

SARS-Cov-2 and the Case for Empirical  Treatment

Published

2020-07-15